ArticlePain reports2025
Jun N-terminal kinase's role in neuropathic pain: C-fiber remodeling and growth-associated protein-43 phosphorylation.
Article in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tetramethylpyrazine modulates the Nrf2/JNK axis to intervene in ferroptosis and neuroinflammation after spinal cord injury: an integrated perspective from antioxidant to regenerative therapy.Molecular biology reports · 2026Review
- Targeting druggable kinases in neuropathic pain.npj drug discovery · 2026Review
- The Specialized Proresolving Mediator Maresin 1 Alleviated Neuropathic Pain Exacerbated by High-Fat Diet via Regulating Neuroinflammation.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Peripheral nerve injury (PNI) often cause neuropathic pain and induces morphological changes in C-fiber terminals. Concurrently, PNI increased growth-associated protein-43 (GAP-43) levels and activated JNK in the injured dorsal root ganglion. A previous study demonstrated that JNK phosphorylates GAP-43 at S96 in growth cones, which are often considered a model for axon elongation. Objectives: The aim of this study was to investigate whether PNI-induced JNK is involved in the phosphorylation of GAP-43 and in the morphological changes of injured C-fiber terminal in dorsal horn. Methods: In this study, we used a rat model of neuropathic pain to examine the expression of phosphorylated GAP-43 at Ser96 (pGAP-43) and to confirm the phosphorylation of JNK (pJNK). Furthermore, we investigated the localization of pGAP-43-positive terminals in the dorsal horn, specifically focusing on their coexpression with L1-CAM-labeled axonal varicosities. We chronically administered a JNK inhibitor intrathecally and assessed its effects on neuropathic pain behavior, expression of pGAP-43, and on injury-induced hypertrophy of L1-CAM-labeled varicosities in the dorsal horn. Results: PNI significantly increased pGAP-43 and pJNK in largely overlapping dorsal root ganglion neurons. In the dorsal horn ipsilateral to the injury, pGAP-43-positive terminals colocalized with L1-CAM-labeled axonal varicosities in laminae I-II. Chronic intrathecal JNK inhibition alleviated neuropathic pain and reduced pGAP-43 immunoreactivity in axon terminals, also preventing injury-induced hypertrophy of L1-CAM-labeled varicosities in the dorsal horn.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.